petrelintide
AssetAlso ZP-8396
Activates amylin receptors to increase satiety, reduce food intake, and regulate blood glucose.
- Stage
- Phase 3
- Modality
- Peptide
- Target
- Insulin/IGF-1 signalling
- 5
- Indications
- 3
- Trials
- 2
- Developers
Indications
5Cardiovascular disease
Phase 3, Recruiting, NCT07843472, clinicaltrials.gov, 8 Oct 2026
Obesity or overweight
Phase 3, Recruiting, NCT07843472, clinicaltrials.gov, 8 Oct 2026
Type 2 diabetes
Phase 3, Recruiting, NCT07843485, clinicaltrials.gov, 8 Oct 2026
2 more
In the full profile
- Targets and what it contains6
- Owner and partners5
- Trials3
- Evidence for its targets7
- Competitors12
- Aging relevance1
- Signals7
Every asset’s record: target, stage, trials and the evidence behind it.